Biosceptre has developed approaches to target cancer-specific epitopes visible on nf-P2X7 which are not visible on other forms of P2X7 . Studies have shown that the nf-P2X7 receptor is present on over 95% of cancer types tested but critically is not present on the surface of non-cancerous cells from normal tissue. Biosceptre’s therapeutics do not cross react with normal P2X7 , indicating that they are unlikely to affect the function of P2X7 in normal cells. Biosceptre has confirmed this through in vitro studies.
Significantly formal pre-clinical toxicology studies for the systemic therapeutic BIL-221s, and topical therapeutic BIL-010t, demonstrate that Biosceptre’s approaches are safe. A Phase I clinical study has demonstrated that BIL-010t is well tolerated and without significant side effects. Furthermore Biosceptre has treated Category A and informed consent patients with systemic antibodies, topical antibodies and by vaccination without significant side effects. Treatment of companion animals has also been shown to be safe.